Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Morphic Holding Inc
(NQ:
MORF
)
56.99
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Morphic Holding Inc
< Previous
1
2
3
4
5
Next >
Morphic Therapeutic Announces Proposed Public Offering
May 02, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
3 Biotech Buyout Targets to Watch
April 29, 2023
The trio all have late-stage therapies with blockbuster potential.
Via
The Motley Fool
4 Analysts Have This to Say About Morphic Holding
April 26, 2023
Via
Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
April 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars
April 25, 2023
Via
Benzinga
Morphic Holding Inc. (NASDAQ: MORF) Highlighted for Surprising Price Action
April 17, 2023
Via
Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) Leading the Way in Monday Trading Based on Percentage Gain
April 17, 2023
Via
Investor Brand Network
Looking Into Morphic Holding's Return On Capital Employed
February 28, 2023
Via
Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 25, 2023
Via
Benzinga
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
April 25, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Holding: Q3 Earnings Insights
November 02, 2022
Morphic Holding (NASDAQ:MORF) reported its Q3 earnings results on Wednesday, November 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
April 25, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
April 24, 2023
Call to discuss topline data from EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis
From
Morphic Therapeutic
Via
GlobeNewswire
7 Biotech Stocks to Buy for 100% Returns
April 09, 2023
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.
Via
InvestorPlace
Where Morphic Holding Stands With Analysts
September 07, 2022
Morphic Holding (NASDAQ:MORF) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Short Volatility Alert: Morphic Holding, Inc.
August 05, 2022
On Thursday, shares of Morphic Holding, Inc. (NASDAQ: MORF) experienced volatile short activity. After the activity, the stock price went up +11.64% to $31.93. The overall sentiment for MORF has been...
Via
Benzinga
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
March 03, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
February 23, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at SVB Leerink Global Healthcare Conference
February 14, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
November 22, 2022
First patient dosed in global study of oral α4β7 integrin inhibitor
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Participation in 2022 Jefferies London Healthcare Conference
November 09, 2022
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
November 02, 2022
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
October 25, 2022
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
October 24, 2022
Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible
From
Morphic Therapeutic
Via
GlobeNewswire
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
October 10, 2022
From
Morphic Therapeutic
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
September 07, 2022
Upgrades
Via
Benzinga
Recap: Morphic Holding Q2 Earnings
August 03, 2022
Morphic Holding (NASDAQ:MORF) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Morphic Holding reported...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.